Antenatal Screening for Down's Syndrome

Penrose LS . The relative effects of paternal and maternal age in mongolism. Journal of Genetics 1933; 27: 219.

Lejeune J Gautier M Turpin R . Etude des chromosomes somatiques de neuf enfants mongoliens. CR Acad Sci Paris 1959; 248: 1721–2.

Steele MW Breg WR . Chromosome analysis of human amniotic-fluid cells. Lancet 1966; i: 383–5.

Valenti C Schutta EJ Kehaty T . Prenatal diagnosis of Down's syndrome. Lancet 1968; ii: 220.

Brock DJH Sutcliffe RG . Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972; ii: 197–9.

Hino M Koki Y Nishi S . Nimpu ketsu naka no alpha-fetoprotein. Igaku No Ayumi 1972; 82: 512.

Brock DJH Bolton AE Monaghan JM . Prenatal diagnosis of anencephaly through maternal serum alpha-fetoprotein measurement. Lancet 1973; ii: 923.

Wald NJ Brock DJH Bonnar J . Prenatal diagnosis of spina bifida and anencephaly by maternal serum alpha-fetoprotein measurement. A controlled study. Lancet 1974; i: 765–7.

Brock DJH Bolton AE Scrimgeour JB . Prenatal diagnosis of spina bifida and anencephaly through maternal plasma alpha-fetoprotein measurement. Lancet 1974; i: 767–9.

Report of UK collaborative study on alpha-fetoprotein in relation to neural tube defects. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977; i: 1323–32.

Merkatz IR Nitowsky HM Macri JN Johnson WE . An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886–94.

Cuckle HS Wald NJ Lindenbaum RH . Maternal serum alpha-fetoprotein measurement. A screening test for Down syndrome. Lancet 1984; i: 926–9.

Cuckle HS Wald NW Thompson SG . Estimating a woman's risk of having a pregnancy with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387–402.

Bogart M Pandian MR Jones OW . Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. PrenatDiagn 1987; 7: 623–30.

Canick J Knight GJ Palomaki GE Haddow JE Cuckle HS Wald NJ . Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95: 330–3.

Wald NJ Cuckle HS Densem JW . Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988; 95: 334–41.

Wald NJ Cuckle HS Densem JW . Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883–8.

Wald NJ Kennard A Densem J Cuckle HS Chard T Butler L . Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992; 305: 391–4.

Haddow JE Palomaki GE Knight GJ . Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992; 327: 588–93.

Wald NJ Densem JW Smith D Klee GG . Four marker serum screening for Down's syndrome. Prenat Diagn 1994; 14: 707–16.

Van Lith JM Pratt JJ Beekhuis JR Mantingh A . Second trimester maternal serum immuno-reactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992; 12: 801–6.

Wald NJ Densem JW George L Muttukrishna S Knight PG . Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996; 16: 143–53.

Wald NJ Densem JW George L . Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997; 17: 285–90.

Wald NJ Wald K Smith D . The extent of Down's syndrome screening in Britain in 1991. Lancet 1992; 340: 494.

Wald N Huttly W Wald K Kennard A . Down's syndrome screening in UK. Lancet 1996; 347: 330.

Brambati B Lanzani A Tului L . Ultrasound and biochemical assessment of first trimester pregnancy. In: Chapman M Grudzinskas JG Chard T , eds. The embryo. Berlin: Springer 1991: 181–94.

Spencer K Macri JN Aitken DA Connor JM . Free β-hCG as first trimester marker for fetal trisomy. Lancet 1992; 339: 1480.

Wald NJ Kennard A Hackshaw A . First trimester serum screening for Down's syndrome. Prenat Diagn 1995; 15: 1227–40.

Benacerraf BR Barss V Laboda LA . A sonographic sign for the detection in second trimester of the fetus with Down's syndrome. Am J Obstet Gynecol 1985; 151: 1078–9.

Szabo J Gellen J . Nuchal fluid accumulation in trisomy 21 detected by vaginosonography in first trimester. Lancet 1990; 336: 1133.

Nicolaides KH Azar G Byrne D Mansur C Marks K . Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. BMJ 1992; 304: 867–9.

Cuckle HS Wald NJ . Principles of screening. In: Wald NJ , ed. Antenatal and neonatal screening, Oxford: Oxford University Press 1984.

Wald NJ Cuckle HS Densem JW . Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883–7.

Wald NJ Hackshaw AK Huttly W Kennard A . Empirical validation of risk screening for Down's syndrome. J Med Screen 1996; 3: 185–7.

Cuckle HS Wald NJ Thompson SG . Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum AFP level. Br J Obstet Gynaecol 1987; 94: 387–402.

Royston P Thompson SG . Model based screening by risk with application to Down's syndrome. Stat Med. 1992; 11: 257–68.

Wald NJ Densem JW Smith D Klee GG . Four marker serum screening for Down's syndrome. Prenat Diagn 1994; 14: 707–16.

Evans MI Chik L O'Brien JE , et cd. MoMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. Am J Obstet Gynecol 1995; 172: 1138–49.

Crossley JS Aitken DA Connor JM . Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophs, alpha-fetoprotein and age. Prenat Diagn 1991; 11: 83–101.

Palomaki GE Neveux LM Haddow JE . Are DADs (discriminant aneuploidy detection) as good as MoMs (multiples of the median) ? Am J Obstet Gynecol 1995; 173: 1895–6.

Reynolds TM . MoMs (mulitples of the median) may know best: there are insufficient data to suggest that DADs (discriminant aneuploidy detection) are superior. Am J Obstet Gynecol 1995; 173: 189.

Merkatz IR Nitowsky HM Macri JN Johnson WE . An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886–94.

Cowchock FS Ruch DA . Low maternal serum AFP and Down syndrome. Lancet 1984; i: 161–2.

Cuckle HS Wald NJ Lindenbaum RH . Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984; i: 926–9. (Updated by reference 52.).

Fuhrmann W Wendt P Weitzel HK . Maternal serum-AFP as screening test for Down syndrome. Lancet 1984; ii: 413.

Guibaud S Bonnet-Capela M Germain D Dumont M Thoulon JM Berland M . Prenatal screening for Down's syndrome. Lancet 1984; ii: 1359–60.

Seller MJ . Prenatal screening for Down syndrome. Lancet 1984; i: 1359.

Tabor A Norgaard-Pedersen B Jacobsen JC . Low maternal serum AFP and Down syndrome. Lancet 1984; ii: 161. (Updated by reference 15.).

Hershey DW Crandall BF Schroth PS . Maternal serum alpha-fetoprotein screening of fetal trisomies. Am J Obstet Gynecol 1985; 153: 224–5.

Murday V Slack J . Screening for Down's syndrome in the North East Thames Region. BMJ 1985; 291: 1315–18.

Spencer K Carpenter P . Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution. BMJ 1985; 290: 1940–3.

Voitlander T Vogel F . Low alpha-fetoprotein and serum albumin levels in Morbus Down may point to a common regulatory mechanism. Hum Genet 1985; 71: 276–7.

Doran TA Cadesky K Wong PY Mastrogiacomo C Capello T . Maternal serum alpha-fetoprotein and fetal autosomal trisomies Am J Obstet Gynecol 1986; 154: 277–81.

Ashwood ER Cheng E Luthy D . Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs. Am J Med Genet 1987; 26: 531–9.

Bogart M Pandian MR Jones OW . Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. PrenatDiagn 1987; 7: 623–30.

Tabor A Larsen SO Nielsen J . Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 636–42.

Canick J Knight GJ Palomaki GE Haddow JE Cuckle HS Wald NJ . Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95: 330–3.

Dix U Gams M Grubisic A Dericks-Tan J Langenbeck U . Maternal serum alpha-fetoprotein in pregnancies with trisomy 18. Z Geburtshilfe Perinat 1988; 192: 231–3.

Wald NJ Cuckle HS Densem JW . Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883–7. (Updated by reference 52.).

Wald NJ Cuckle HS Densem JW . Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988; 95: 334–41. (Updated by reference 52.).

Bogart M Golbus M Sorg N Jones OW . Human chorionic gonadotropin levels in pregnancies with aneuploid fetuses. Prenat Diagn 1989; 9: 379–84. (Data on total hCG updated by reference 25.).

Del Junco D Greenberg F Darnule A . Statistical analysis of maternal age, maternal serum alpha fetoprotein, β human chorionic gonadotropin, and unconjugated estriol for Down syndrome screening in midtrimester [abstract]. Am J Hum Genet 1989; 45: A257.

Fisher RA Suppnick CK Peabody CT Zapp AR Loomis Do Helwick Schehr AB . Maternal serum chorionic gonadotrophin, unconjugated estriol and alpha-fetoprotein in Down syndrome pregnancies [abstract]. Am J Hum Genet 1989; 45: A259.

Osathanondh R Canick JA Abell KB . Second trimester screening for trisomy 21. Lancet 1989; ii: 52.

Petrocik E Wassman R Kelly J . Prenatal screening for Down syndrome using maternal serum human chorionic gonadotropin levels. Am J Obstet Gynecol 1989; 161: 1168–73.

Bartels I Thiele M Bogart M . Maternal serum HCG and SP1 in pregnancies with fetal aneuploidy. Am J Med Genet 1990; 37: 261–4.

Heyl PS Miller W Canick JA . Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1990; 76: 1025–31.

Jacobs S Giles W . Down's syndrome and low maternal serum alpha-fetoprotein. Aust NZ J Obstet Gynaecol 1990; 30: 335.

Macri J Kasturi RV Krantz BS . Maternal serum Down syndrome screening: free B-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990; 163: 1248–53.

Macri JN Kasturi RV Krantz DA Cook EJ Sunderji SG Larsen JW . Maternal serum Down syndrome screening: unconjugated estriol is not useful. Am J Obstet Gynecol 1990; 162: 672–3.

Muller F Boue A . A single chorionic gonadotropin assay for maternal serum screening for Down's syndrome. Prenat Diagn 1990; 10: 389–98.

Norgaard-Pedersen B Larsen SO Arends J Svenstrup B Tabor A . Maternal serum markers in screening for Down syndrome. Clin Genet 1990; 37: 35–43. (Data on AFP and total hCG updated by reference 51.).

Suchy SF Yeager MT . Down syndrome screening in women under 35 with maternal serum hCG. Obstet Gynecol 1990; 76: 20–4.

Bogart MH Jones OW Felder RA . Prospective evaluation of maternal serum human chorionic gonadotrophin levels in 3428 pregnancies. Am J Obstet Gynecol 1991; 165: 663–6.

Crossley JA Aitken DA Connor JM . Free β hCG and prenatal screening for chromosome abnormalities. J Med Genet 1991; 28: 570.

Crossley JA Aitken DA Connor JM . Prenatal screening chorionic gonadotrophin, alpha-fetoprotein, and age. PrenatDiagn 1991; 11: 83–101.

Kellner LH Weiss RR Neuer M Bock JL . Maternal serum screening using alpha-fetoprotein, beta-human chorionic gonadotropin and unconjugated estriol (AFP+) in the second trimester [abstract]. Am J Obstet Gynecol 1991; 164: A636.

Lewis M Faed MJW Howie PW . Screening for Down's syndrome based on individual risk. BMJ 1991; 303: 551–3.

MacDonald ML Wagner RM Slotnick RN . Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol 1991; 77: 63–8.

Mancini G Perone M Dall'Amico D . Screening for fetal Down's syndrome with maternal serum markers - an experience in Italy. PrenatDiagn 1991; 11: 245–52.

Miller CH O'Brien TJ Chatelain S Butler BB Quirk JG . Alteration in age-specific risks for chromosomal trisomy by maternal serum alpha-fetoprotein and human chorionic gonadotropin screening. Prenat Diagn 1991; 11: 153–8.

Spencer K . Evaluation of an assay of the free β-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clin Chem 1991; 37: 809–14.

Zeitune M Aitken DA Crossley JA Yates JRW Cooke A Ferguson-Smith MA . Estimating the risk of a fetal autosomal trisomy at mid-trimester using maternal serum alphafetoprotein and age: a retrospective study of 142 pregnancies. Prenat Diagn 1991; 11: 847–57.

Herrou M Leporrier N Leymarie P . Screening for fetal Down syndrome with maternal serum hCG and oestriol: a prospective study. Prenat Diagn 1992; 12: 887–92.

Mancini G Perona M Dall'Amico C Bollati C Fulvia A Carbonara A . hCG, AFP, and uE, patterns in the 14–20th weeks of Down's syndrome pregnancies. Prenat Diagn 1992; 12: 619–24.

Ryall RG Staples AJ Robertson EF Pollard AC . Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses. Prenat Diagn 1992; 12: 251–61.

Spencer K Coombes EJ Mallard AS Ward A Milford . Free beta human chorionic gonadotrophin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992; 29: 506–18.

Spencer K Macri JN . Early detection of Down's syndrome using free beta human chorionic gonadotrophin. Ann Clin Biochem 1992; 29: 349–50.

Crossley JA Aitken DA Connor JM . Second trimester unconjugated oestriol levels in maternal serum from chromosomally abnormal pregnancies using an optimised assay. PrenatDiagn 1993; 13: 271–80.

Spencer K . Free a-subunit of human chorionic gonadotrophin in Down syndrome. Am J Obstet Gynecol 1993; 168: 1.

Stone S Henely R Reynolds T John R . A comparison of total and free β-hCG assays in Down syndrome screening. PrenatDiagn 1993; 13: 535–7.

Norgaard-Pedersen B Alfthan H Arends J . A new simple and rapid dual assay for AFP and the free β-subunit of hCG in screening for Down's syndrome. Clin Genet 1994; 45: 1–4.

Wald NJ Densem JW Smith D Klee GG . Four marker serum screening for Down's syndrome. Prenat Diagn 1994; 14: 707–16.

Forest JC Masse J Rousseau F . Screening for Downs syndrome during the first and second trimesters: impact of risk estimation parameters. Clin Biochem 1995; 28: 443–9.

Kellner LH Weiss RR Weiner Z . The advantages of using triple-marker screening for chromosomal abnormalities. Am J Obstet Gynecol 1995; 172: 831–6.

Wenstrom KD Desai R Owen J DuBard MB Boots L . Comparison of multiple marker screening with amniocentesis for the detection of fetal aneuploidy in women 5 35 years old. Am J Obstet Gynecol 1995; 173: 1287–92.

Aitken DA Wallace EM Crossley JA . Dimeric inhibin-A as a marker for Down's syndrome in early pregnancy. N Engl J Med. 1996; 334: 1231–6.

Cuckle HS Holding S Jones R Groome NP Wallace EM . Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996; 16: 1095–100.

Lambert-Messerlian GM Canick JA Palomaki GE Schneyer AL . Second trimester levels of maternal serum inhibin-A, total inhibin, a inhibin precursor and activin in Down's syndrome pregnancies. J Med Screen 1996; 3: 58–62.

Spencer K Wallace Em Ritoe S . Second trimester dimeric inhibin-A in Down's syndrome screening. Prenat Diagn 1996; 16: 1101–10.

Wald N Densem J George L Muttukrishna S Knight PG . Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996; 16: 143–53.

Wald NJ Densem JW George L . Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997; 17: 285–90.

Wallace E Swanston I Grant V . Second trimester screening for Down's syndrome using serum dimeric inhibin-A. Clin Endocrinol 1996; 44: 17–21.

Wenstrom KD Owen J Boots L . Second trimester maternal serum CA-125 versus estriol in the multiple-marker screening test for Down syndrome. Obstet Gynecol 1997; 89: 359–63. (Data on AFP, uE15 and total hCG are in reference 55.).

Spencer K . Maternal serum CA125 is not a second trimester marker for Down's syndrome. Ann Clin Biochem 1991; 28: 299–300.

Hogdall CK Arends J Norgaard-Pedersen B Smidt-Jensen S Larsen SO . CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters. Prenat Diagn 1992; 12: 223–7.

Van Blerk M Smitz J de Catte L Kumps C van der Eist J van Steirteghem AC . Second trimester cancer antigen 125 and Down's syndrome. Prenat Diagn 1992; 12: 1062–6.

Van Lith JMM Mantingh A de Bruijn HWA . Maternal serum CA 125 levels in pregnancies with chromosomally-normal and -abnormal fetuses. Prenat Diagn 1993; 13: 1123–31.

Bartels I Lindemann A . Maternal levels of pregnancy-specific beta-1 glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet 1988; 80: 46–8.

Knight GJ Palomaki GE Haddow JE Johnson AM Osathanondh P Canick JA . Maternal levels of the placental products hCG, hPL, SP1 and progesterone are all elevated in cases of fetal Down syndrome [abstract]. Am J Hum Genet 1989; 45: A257.

Wald NJ Cuckle HS Densem J . Maternal serum specific beta-1-glycoprotein in pregnancies associated with Down's syndrome. Lancet 1989; ii: 450.

Petrocik E Wassman ER Lee J Jack Kelly JC . Second trimester maternal serum pregnancy specific beta-1 glycoprotein (SP-1) levels in normal and Down syndrome pregnancies. Am J Hum Genet 1990; 37: 114–18.

Graham GW Crossley JA Aitken DA Connor JM . Variation in the levels of pregnancy specific beta-1-glycoprotein in maternal serum from chromosomally abnormal pregnancies. Prenat Diagn 1992; 12: 505–12.

Qin QP Christiansen M Ngugen TH Sorensen S Larsen SO Norgaard-Pedersen B . Schwangerschaftsprotein 1 (SP1) as a maternal serum marker for Down syndrome in the first and second trimesters. Prenat Diagn 1997; 17: 101–8.

Van Lith JMM Pratt JJ Beekhuis JR . , Mantingh A. Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992; 12: 801–6.

Spencer K Wood PJ Anthony FW . Elevated levels of maternal serum inhibin immunore activity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993; 30: 219–20.

Cuckle HS Holding S Jones R . Maternal serum inhibin levels in second trimester Down's syndrome pregnancies. Prenat Diagn 1994; 14: 387–90.

Cuckle HS Lilford RJ Teisner B Holding S Chard T Grudzinskas JG . Pregnancy associated plasma protein A in Down's syndrome. BMJ 1992; 305: 425.

Wald N Voller A . Pregnancy associated plasma protein A in Down's syndrome. BMJ 1992; 305: 425.

Knight GJ Palomaki GE Haddow JE Bersinger NA Schneider H . Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy. Prenat Diagn 1993; 13: 222–3.

Grozdea J Vergnes H Martin J . Urea-resistant neutrophil alkaline phosphatase in mothers with trisomy 21 pregnancy. Lancet 1983; ii: 799–80.

Cuckle HS Wald NJ Goodburn SF Sneddon J Amess JAL Dunn SC . Measurement of activity of urea resistant alkaline phosphatase as an antenatal screening test for Down's syndrome. BMJ 1990; 301: 1024–6.

DerSimonian R Laird N . Meta-analysis in clinical trials. ControlClin Trials 1986; 7: 177–88.

Cuckle H . Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995; 15: I057–65.

Wald NJ Hackshaw AK . Risk estimation in Down's syndrome screening. Prenat Diagn 1996; 16: 1055–57.

Cuckle HS . Risk estimation in Down's syndrome screening. Prenat Diagn 1995; 15: 1057–65.

Wald NJ Cuckle H Boreham J Terzian E . The effect of maternal weight on maternal serum alpha-fetoprotein levels. Br J Obstet Gynaecol 1981; 88: 1094–6.

Haddow JE Kloza EM Knight GJ Smith DE . Relation between maternal weight and serum alpha-fetoprotein concentration during the second trimester. Clin Chem 1981; 27: 133–4.

Macri JN Kasturi RV Krantz DA Koch KE . Maternal serum alpha-fetoprotein screening, maternal weight and detection efficiency. Am J Obstet Gynecol 1986; 155: 758–60.

Reynolds TM Penney MD John R . The effect of weight correction on risk calculations for Down's syndrome screening. Ann Clin Biochem 1991; 28: 245–9.

Wald NJ Cuckle HS Densem JW Kennard A Smith D . Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol 1992; 99: 144–9.

Bartels I Hoppe-Sievert B Bockel B Herold S Caesar J . Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotrophin and unconjugated oestriol to maternal weight and smoking. Prenat Diagn 1993; 13: 123–30.

Wart HC Wald NJ Smith D Kennard A Densem J . Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 1996; 16: 691–8.

Neveux LM Palomaki GE Larrivee DA Knight GJ Haddow JE . Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996; 16: 1115–19.

Reece EA Davis N Mahoney MJ Baumgarten A . Maternal serum alpha-fetoprotein in diabetic pregnancy: correlation with blood glucose control. Lancet 1987; ii: 275.

Greene MF Haddow JE Palomaki GE Knight GJ . Maternal serum alpha-fetoprotein levels in diabetic pregnancies. Lancet 1988; ii: 345–6.

Canick JA Panizza DS Palomaki GE . Prenatal screening for Down syndrome using AFP, uE3 and hCG: effect of maternal race, insulin-dependent diabetes and twin pregnancy [abstract]. Am J Hum Genet 1990; 47: A270.

Sunderji S Macri JN . Second trimester MSAFP in insulin dependent diabetes. Am J Obstet Gynecol 1992; 166: 353.

Henriques CU Damm P Tabor A Pedersen JF Molsted-Pedersen L . Decreased alpha-fetoprotein in amniotic fluid and maternal serum in diabetic pregnancy. Obstet Gynecol 1993; 82: 960–4.

Palomaki GE Knight GJ Haddow JE . Human chorionic gonadotropin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. Prenat Diagn 1994; 14: 65–8.

Selby C Stirland B Marenah CB . Down's screening in insulin dependent diabetics: should we be correcting AFP? [abstract]. In: Proceedings of the ACB National Meeting. United Kingdom: Association of Clinical Biochemists 1995: A67.

Crossley JA Berry E Aitken DA Connor JM . Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme. Prenat Diagn 1996; 16: 1039–42.

Wald NJ Cuckle HS Densem JW Stone RB . Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1992; 99: 51–3.

Wald NJ Watt HC George L . Maternal serum inhibin-A in pregnancies with insulin dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn 1996; 16: 923–6.

Wald NJ Densem JW Cheng R Collishaw S . Maternal serum free a- and free β-human chorionic gonadotrophin in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn 1994; 14: 835–7.

Knight GJ Kloza EM Smith DE Haddow JE . Efficiency of human placental lactogen and AFP measurement in twin pregnancy detection. Am J Obstet Gynecol 1981; 141: 585–6.

Ghosh A Woo JSK Rawlinson HA Ferguson-Smith MA . Prognostic significance of raised serum AFP levels in twin pregnancies. Br J Obstet Gynaecol 1982; 89: 817–20.

Librach CL Doran TA Benzie RJ Jones JM . Genetic amniocentesis in seventy twin pregnancies. Am J Obstet Gynecol 1984; 148: 585.

Walker EM Patel NB . Maternal serum AFP, birthweight and perinatal death in twin pregnancy. Br J Obstet Gynaecol 1986; 93: 1191–3.

Alpert E Greenberg F Contant C . Serum hCG, AFP and unconjugated estriol levels in twin pregnanices in mid-trimester [abstract]. Am J Hum Genet 1990; 47: A267.

Johnson JM Harman CR Evans JA MacDonald K Manning FA . Maternal serum AFP in twin pregnancy. Am J Obstet Gynecol 1990; 162: 1020–5.

Dar H David M Merksamer R Israel N Borochowitz Z . Maternal serum AFP and hCG in twin pregnancies. Am J Hum Genet 1991; 49: S328.

Nieb B Joyce A Burton BK . Mid-trimester hCG and uE3 levels in twin pregnancies. Am J Hum Genet 1991; 49: S221.

Wald NJ Cuckle HS Wu T George L . Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1991; 8: 905–8.

Spencer K Salonen R Muller F . Down's syndrome screening in multiple pregnancies using alpha-fetoprotein and free beta hCG. Prenat Diagn 1994; 14: 537–42.

Neveux LM Palomaki GE Knight GJ Haddow JE . Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996; 16: 29–35.

Bogart MH Jones OW Felder RA . Prospective evaluation of maternal serum human chorionic gonadotropin levels in 3428 pregnancies. Am J Obstet Gynecol 1991; 16S: 663–7.

Nebiolo LM Adams WB Miller SL Milunsky A . Maternal serum human chorionic gonadotropin levels in twin pregnancies. Prenat Diagn 1991; 11: 463–6.

Wald NJ Densem JW . Maternal serum free alpha-human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1994; 14: 717–19.

Wald NJ Densem JW . Maternal serum free beta-human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1994; 14: 319–20.

Watt HC Wald NJ . Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1996; 16: 927–9.

Macri JN Weiss RR Elligers KW Federgreen WR . Racial differences in maternal serum AFP. Lancet 1976; i: 207–8.

Crandall BF Lebherz TB Schroth PC Matsumoto M . Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight. Clin Chem 1983; 29: 531–3.

Johnson AM . Racial differences in maternal serum alpha-fetoprotein screening. In: Mizejewski GJ Porter IH , eds. Alpha-fetoprotein and congential disorders. New York: Academic Press 1985: 183–96.

Baumgarten A . Racial differences and biological significance of maternal serum AFP. Lancet 1986; ii: 573.

Wald NJ Cuckle HS . Recent advances in screening for neural tube defects and Down's syndrome. Ballieres Clin Obstet Gynaecol 1987: 649–76.

O'Brien JE Dvorin E Drugan A Johnson MP Yaron Y Evans MI . Race-ethnicity-specific variation in multiple-marker biochemical screening: AFP, hCG and estriol. Obstet Gynecol 1997; 89: 355–8.

Simpson JL Elias S Morgan CD Shulman L Umstot E Anderson RN . Second trimester maternal serum human chorionic gonadotrophin and unconjugated oestriol levels in blacks and whites. Lancet 1990; i: 1459–60.

Burton BK Nieb B . Effect of maternal race and weight (wt) on hCG and uE3 levels in the mid-trimester [abstract]. Am J Hum Genet 1991; 49: 212.

Kulch P Keener S Matsumoto M Crandall BF . Racial differences in maternal serum human chorionic gonadotropin and unconjugated oestriol levels. Prenat Diagn 1993; 13: 191–5.

Muller F Boue A . A single chorionic gonadotrophin assay for maternal serum screening for Down's syndrome. Prenat Diagn 1990; 10: 389–98.

Shapiro LM Skinner LG Philips HV Whitfield CR . Racial differences in maternal serum alpha-fetoprotein. Lancet 1975; ii: 1142.

Cuckle HS Nanchahal K Wald NJ . Maternal serum AFP and ethnic origin. Br J Obstet Gynaecol 1987; 94: 1111–12.

Cuckle HS Wald NJ Densem JW . The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 1990; 97: 272–6.

Palomaki GE Knight GJ Haddow JE Canick JA Wald NJ Kennard A . Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol and hCG: impact on Down syndrome screening. Obstet Gynecol 1993; 81: 675–8.

Spencer K . Correcting for smoking in Down's syndrome screening [abstract]. Clin Chem 1993; 39: A1169.

Cuckle HS Alberman W Wald NJ Royston P Knight G . Maternal smoking habits and Down's syndrome. Prenat Diagn 1990; 10: 561–7.

Haddow JE Palomaki GE Knight GJ . Effect of parity on huma chorionic gonadotrophin levels and Down's syndrome screening. J Med Screen 1995; 2: 28–30.

Zimmermann R Streicher A Huch R Huch A . Effect of gravidity and parity on the parameters used in serum screening for trisomy 21. Prenat Diagn 1995; 15: 781–2.

Wald NJ Watt HC . Serum markers for Down's syndrome in relation to number of previous births and maternal age. Prenat Diagn 1996; 16: 699–703.

Spencer K . The influence of gravidity in Down's syndrome screening with free beta-hCG. Prenat Diagn 1995; 15: 87–9.

Barkai G Goldman B Ries L Chaki R Cuckle HS . Effect of gravidity on maternal serum markers for Down's syndrome. Prenat Diagn 1996; 16: 319–22.

Cuckle HS Wald NJ . Screening for Down's syndrome. In: Lilford RJ , ed. Prenatal diagnosis and prognosis. London: Butterworth 1990: 67–92.

Hackshaw AK Densem J Wald NJ . Repeat maternal serum testing for Down's screening using multiple markers with special reference to free alpha and free beta hCG. Prenat Diagn 1995; 14: 1125–30.

Hackshaw AK Densem J Wald NJ . Correction to repeat maternal serum testing for Down's screening using multiple markers with special reference to free alpha and free beta hCG. Prenat Diagn (in press).

Holding S Cuckle H . Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy. Prenat Diagn 1994; 14: 321–4.

Spencer K . Between-pregnancy biological variability of maternal serum AFP and free α-hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 1997; 17: 39–45.

Barkai G Goldman B Ries L Chaki R Dor J Cuckle H . Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996; 16: 1111–14.

Muller F Aegerter P Boue A . Prospective maternal serum hCG screening for the risk of fetal chromosome anomalies and of subsequent fetal and neonatal deaths. Prenat Diagn 1993; 13: 29–43.

Ribbet LSM Kornman LH De Wolf BTHM . Maternal serum screening for fetal Down's syndrome in IVF pregnancies. Prenat Diagn 1996; 16: 35–8.

Spencer K Noble P Snijders RJM Nicolaides KH . First trimester urine free beta hCG, beta core and total oestriol in pregnancies affected by Down's syndrome: implications for first trimester screening with nuchal translucency and serum free beta hCG. Prenat Diagn 1997; 17: 525–8.

Kellner LH Canick JA Palomaki GE . Maternal urine screening for fetal Down syndrome: comparison of beta-core fragment, free β subunit and hCG [abstract]. Am J Obstet Gynecol 1996; 174: 446A.

Cuckle HS Iles RK Sehmi IK Oakley RE Davies S Ind T . Urinary multiple marker screening for Down's syndrome. Prenat Diagn 1995; 15: 745–51.

Canick JA Kellner LH Saller DN Palomaki GE Walker RP Osathanondh R . Second trimester levels of maternal urinary gonadotropin peptide in Down syndrome pregnancy. Prenat Diagn 1995; 15: 739–44.

Canick JA Kellner LH Sailer DN . A second level evaluation of maternal urinary gonadotropin peptide as a marker for second trimester Down syndrome screening [abstract]. 3rd Joint Clinical Genetics Meeting, March of Dimes/ACMG. USA: American College of Medical Genetics 1996: A156.

Isozaki T Palomaki GE Bahado-Singh RO Cole LA . Screening for Down syndrome pregnancy using β-core fragment: prospective study. Prenat Diagn 1997; 17: 407–13.

Spencer K Aitken DA Macri JN Buchanan PD . Urine free beta hCG and beta core in pregnancies affected by Down's syndrome. Prenat Diagn 1996; 16: 605–13.

Hayashi M Kozu H . Maternal urinary beta-core fragment of hCG/creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. Prenat Diagn 1995; 15: 11–16.

Kornman LH Morssink LP Wortelboer MJM . Maternal urinary β-core hCG in chromosomally abnormal pregnancies in the first trimester. Prenat Diagn 1997; 17: 135–9.

Macintosh MCM Nicolaides KH Noble P Chard T Gunn L Iles R . Urinary β-core hCG: screening for aneuploidies in early pregnancy (11-14 weeks' gestation). Prenat Diagn 1997; 17: 401–5.

Kellner LH Canick JA Sailer DN . Second trimester levels of maternal urinary total estriol (TE,) in Down syndrome pregnancy [abstract]. In: Recent advances in prenatal diagnosis for aneuploidy. Amsterdam meeting, 1996, Abstract 15.

Simpson JL Elias S . Isolating fetal cells in maternal circulation for prenatal diagnosis. Prenat Diagn 1994; 14: 1229–42.

Bianchi DW Demaria M Vadnais TJ Zickwolf GK Weil GJ . Trials in recovering fetal cells from maternal blood. In: Zakut H , ed. 7th International conference on early prenatal diagnosis. Bologna: Monduzzi Editöre 1994: 7–14.

Simpson JL Elias S . Fetal cells in maternal blood: overview and historical perspective. Ann NY Acad Sci. 1994; 731: 1–10.

Elias S Price J Douxter M Wachtel S Tharapel A Simpson JL . First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet 1992; 340: 1033.

Ganshirt-Ahlert D Borjesson-Stoll R Burschyk M . Detection of fetal trisomies 21 and 18 from maternal blood using triple gradient and magnetic cell sorting. Am J Reprod Immunol 1994; 30: 194–201.

Simpson JL Elias S . Isolating fetal cells from maternal blood: advances in prenatal diagnosis through molecular technology. JAMA 1993; 270: 2357–61.

Valerio D Aiello R Altien V Malato AP Fortunato A Canazio A . Culture of fetal erythroid progenitor cells from maternal blood for non-invasive prenatal genetic diagnosis. Prenat Diagn 1996; 16: 1073–82.

Ferguson-Smith MA Zheng YL Carter NP . Simultaneous immunophenotyping and FISH on fetal cells from maternal blood. Ann NY Acad Sci; 1994; 731: 73–9.

Haddow JE Palomaki GE Knight GJ . Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992; 327: 588–93.

Phillips OP Elias S Schulman LP Andersen RN Morgan CD Simpson JL . Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992; 80: 353–8.

Wald NJ Kennard A Densem JW Cuckle HS Chard T Butler L . Antental maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992; 305: 391–4.

Cheng EY Luthy DA Zebelman AM Williams MA Liepp-Man RE Hickok DE . A prospective evaluation of a second-trimester screening test for Down syndrome using maternal serum alpha-fetoprotein, hCG and unconjugated estriol. Obstet Gynecol 1993; 81: 72–7.

Burton BK Prins GS Verp MS . A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol. Am J Obstet Gynecol 1993; 169: 526–30.

Pescia G Dao MH Wekhs D . Le triple depistage del la trisomie 21: resultats prospectifs de 7039 evaluations. Rev Med Suisse Romande 1993; 113: 277–80.

Piggott M Wilkinson P Bennett J . Implementation of an antenatal screening programme for Down's syndrome in two districts (Brighton and Eastbourne). J Med Screen 1994; 1: 45–9.

Goodbum SF Yates JRW Raggatt PR . Second trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotropin and unconjugated oestriol: experience of a regional programme. Prenat Diagn 1994; 14: 391–402.

Mancini G Perona M Dall'Amico D . Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. Int I Clin Lab Res. 1994; 14: 49–53.

Kellner LH Weiss RR Weiner Z . The advantages of using triple-marker screening for chromosomal abnormalities. Am J Obstet Gynecol 1995; 172: 831–6.

Macintosh MCM Wald NJ Chard T . The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 1995; 102: 798–801.

Macintosh MCM Wald NJ Chard T . The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103: 1172–3.

Dawson AJ Jones G Matharu MS . Serum screening for Down's syndrome. Br J Obstet Gynaecol 1993; 100: 875–7.

Burn J . Maternal serum screening for Down's syndrome: audit of process and outcome in the northern region of England. Report of the RCOG working party on biochemical markers and detection of Down's syndrome. London: RCOG Press 1993.

Beekhuis JR . Maternal serum screening for fetal Down's syndrome and neural tube defects. A prospective study performed in the north of the Netherlands. The Netherlands: Gronigen University 1993. (PhD thesis.).

Crossley JA Aitken DA Berry E Connor JM . Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland. J Med Screen 1994; 1: 180–3.

Mooney RA Peterson J Franch CA Sailer DN Arvan DA . Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trim ester screening program for Down syndrome. Obstet Gynecol 1994; 84: 298–303.

Spencer K Carpenter P . Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. BMJ 1993; 307: 764–9.

Macri JN Spencer K Garver K . Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome. Prenat Diagn 1994; 14: 97–103.

Palomaki GE Neveux LM Haddow JE . Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials? J Med Screen 1996; 3: 12–17.

Verloes A Schoo R Herens C Vinters A Koulischer L . A prenatal trisomy 21 screening programme using α-fetoprotein, human chorionic gonadotropin, and freees-triol assays on maternal dried blood. Am J Obstet Gynecol 1995; 172: 167–74.

Macri JN Anderson RW Krantz DA Larsen JW Buchanan PD . Prenatal maternal dried blood screening with a-fetoprotein and free β-human chorionic gonadotropin for neural tube defect and Down syndrome. Am J Obstet Gynecol 1996; 174: 566–72.

Haddow JE Palomaki GE . Similarities in women's decision making in the US and UK during prenatal screening for Down's syndrome. Prenat Diagn 1996; 16: 1161–2.

Vintzileos AM Egan JFX . Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography. Am J Obstet Gynecol 1995; 172: 837–44.

Benacerraf BR Frigoletto FD Cramer DW . Down syndrome: sonographic sign for diagnosis in the second trimester fetus. Radiology 1987; 163: 811–13.

Perrella R Duerinck AJ Grant EG Tessler F Tabsch K Crandall BF . Second trimester sonographic diagnosis of Down syndrome: role of femur-length shortening and nuchal fold thickening. American Journal of Radiology 1988; 151: 981–5.

Benacerraf BR Cnann A Gelman R Laboda LA Frigoletto FD . Can sonographers reliably identify anatomic features associated with Down syndrome in fetuses? Radiology 1989; 173: 377–80.

Lynch L Berkowitz GS Chitkara U Wilkins IA Mehalek KE Berkowitz RL . Ultrasound detection of Down syndrome: is it really possible? Obstet Gynecol 1989; 73: 267–70.

Ginsberg N Cadkin A Pergament E Verlinsky Y . Ultrasonographic detection of the second-triemster fetus with trisomy 8 and trisomy 21. Am J Obstet Gynecol 1990; 163: 1186–90.

Nyberg DA Resta RG Luthy DA Hickok DE Mahony BS Hirsch JH . Prenatal sonographic findings of Down syndrome: review of 94 cases. Obstet Gynecol 1990; 76: 370–7.

Benacerraf BR Neuberg D Frigoletto FD . Humeral shortening in second-trimester fetuses with Down syndrome. Obstet Gynecol 1991; 77: 223–7.

Crane JP Gray DL . Sonographically measured nuchal skinfold thickness as a screening tool for Down syndrome: results of a prospective clinical trial. Obstet Gynecol 1991; 77: 533–6.

Benacerraf BR Neuberg D Bromley B Frigoletto FD . Sonographic scoring index for prenatal detection of chromosomal abnormalities. J Ultrasound Med. 1992; 11: 449–58.

Kirk JS Comstock CH Fassnacht MA Yang SS Lee W . Routine measurement of nuchal thickness in the second trimester. Journal of Maternal Fetal Medicine 1992; 1: 82–6.

De Vore GR Alfi O . The association between an abnormal nuchal skinfold, trisomy 21 and ultrasound abnormalities identified during the second trimester of pregnancy. Ultrasound Obstet Gynecol 1993; 3: 387–94.

Lockwood CJ Lynch L Chidini QA . The effect of fetal gender on the prediction of Down syndrome by means of maternal serum β-fetoprotein and ultrasonographic parameters. Am J Obstet Gynecol 1993; 169: 1190–7.

Benacerraf BR Nadel A Bromley B . Identification of second trimester fetuses with autosomal trisomy by the use of a sonographic scoring index. Radiology 1994; 193: 135–40.

Donnenfeld AE Carlson DE Palomaki GE Librizzi RJ Weiner S Platt LD . Prospective multicenter study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies. Obstet Gynecol 1994; 84: 844–7.

Gray DL Crane JP . Optimal nuchal skin-fold threshold based on gestational age for prenatal detection of Down syndrome. Am J Obstet Gynecol 1994; 171: 1282–6.

Watson WJ Miller RC Menard K . Ultrasonographic measurement of fetal nuchal skin to screen for chromosomal abnormalities. Am J Obstet Gynecol 1994; 170: 583–6.

Bahado-Singh RO Goldstein I Uerpairojkit B Copel JA Mahoney MJ Baumgarten A . Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnornal triple-screen results. Am J Obstet Gynecol 1995; 173: 1106–10.

De Vore GR Alfi O . The use of color doppler ultrasound to identify fetuses at increased risk of trisomy 21. An alternative for high risk patients who decline genetic amniocentesis. Obstet Gynecol 1995; 85: 378–86.

Grandjean H Sarramon MF , AFDPHE Study Group. Sonographic measurement of nuchal skinfold thickness for determination of Down syndrome in the second trimester fetus: a multicenter prospective study. Obstet Gynecol 1995; 85: 103–6.

Borrell A Costa D Martinez JM Delgado RD Forguell T Fortuny A . Criteria for fetal nuchal thickness cut-off: a re-evaluation. Prenat Diagn 1997; 17: 23–9.

Toi A Simpson GF Filly RA . Ultrasonically evident fetal nuchal skin thickening: is it specific for Down syndrome? Am J Obstet Gynecol 1987; 157: 150–3.

Nyberg DA Luthy DA Cheng EY Sheley RC Resta RG Williams MA . Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers. Am J Obstet Gynecol 1995; 173: 1030–5.

Benacerraf B Gelman R Frigoletto FD . Sonographic identification of second trimester fetuses with Down's syndrome. N Engl J Med. 1987; 317: 1371–6.

Cuckle H Wald N Quinn J Royston P Butler L . Ultrasound fetal femur length measurement in the screening for Down syndrome. Br J Obstet Gynaecol 1989; 96: 1373–8.

Dicke JM Gray DL Songster GS Crane JP . Fetal biometry as a screening tool for the detection of chromosomally abnormal pregnancies. Obstet Gynecol 1989; 74: 726–9.

Hill L Guzick D Belfar HL Hixson J Rivello D Rusnak J . The current role of sonography in the detection of Down syndrome. Obstet Gynecol 1989; 74: 620–3.

LaFollette L Filly RA Anderson R Golbus MS . Fetal femur length to detect trisomy 21. A reappraisal. J Ultrasound Med. 1989; 8: 657–60.

Peters MT Lockwood CJ Miller WA . The efficacy of fetal sonographic biometry in Down syndrome screening. Am J Obstet Gynecol 1989; 161: 297–300.

Grist TM Fuller RW Albiez KL Bowie JD . Femur length in the US prediction of trisomy 21 and other chromosomal abnormalities. Radiology 1990; 174: 837–9.

Nyberg DA Resta RG Hickok DE Hollenbach KA Luthy DA Mahony BS . Femur length shortening in the detection of Down's syndrome: is prenatal screening feasible? Am J Obstet Gynecol 1990; 162: 1247–52.

Rodis JF Vintzileos AM Fleming AD . Comparison of humerus length with femur length in fetuses with Down's syndrome. Am J Obstet Gynecol 1991; 165: 1051–6.

Biagiotti R Periti E Cariati E Nannini R . Echogenic measuring of the length of the fetal femur length in the screening for Down syndrome. Minerva Ginecol 1992; 44: 609–12.

Rotmensch S Luo JS Liberati M Belanger K Mahoney MJ Hobbins JC . Fetal humeral length to detect Down syndrome. Am J Obstet Gynecol 1992; 166: 1330–4.

Nyberg DA Resta RG Luthy DA Hickok DE Williams MA . Humerus and femur length shortening in the detection of Down's syndrome. Am J Obstet Gynecol 1993; 168: 534–8.

Biagiotti R Periti E Cariati E . Humerus and femur length in fetuses with Down syndrome. Prenat Diagn 1994; 14: 429–34.

Johnson MP Michaelson JE Barr M . Combining humerus and femur length for improved ultrasonographic identification of pregnancies at increased risk for trisomy 21. Am J Obstet Gynecol 1995; 172: 1229–35.

Lockwood CJ Benacerraf B Krinsky A . A sonographic screening method for Down syndrome. Am J Obstet Gynecol 1987; 157: 803–8.

Brumfield CGt Hauth JC Cloud GA Davis RO Henson BV Cosper P . Sonographic measurements and ratios in fetuses with Down syndrome. Obstet Gynecol 1989; 73: 644–6.

Marquette GP Boucher M Desrochers M Dellaire L . Screening for trisomy 21 with ultrasonographic determination of biparietal diameter/femur length ratio. Am J Obstet Gynecol 1990; 163: 1604–5.

Shah GS Ecki CJ Stinson SK Woods JR . Biparietal diameter to femur length ratio, cephalic index and femur length measurements: not reliable screening techniques for Down syndrome. Obstet Gynecol 1990; 75: 186–8.

Benacerraf BR Mandell J Estroff JA Harlow BL Frigoletto FD . Fetal pyelectasis: a possible association with Down syndrome. Obstet Gynecol 1990; 76: 58–60.

Corteville JE Dicke JM Crane JP . Fetal pyelectasis and Down syndrome: is genetic amniocentesis warranted? Obstet Gynecol 1992; 79: 770–2.

Bromley B Doubilet P Frigoletto FD Krauss C Estroff JA Banacerrad BR . Is fetal hyperechoic bowel on second trimester sonogram an indication for amniocentesis? Obstet Gynecol 1994; 83: 647–51.

Lettieri L Rodis JF Vintizileos AM Feeney L Ciarleglio L Craffey A . Ear length in second trimester aneuploid fetuses. Obstet Gynecol 1993; 81: 57–60.

Benacerraf BR Harlow BL Frigoletto FD . Hypoplasia of the middle phalanx of the fifth digit. J Ultrasound Med. 1990; 9: 389–94.

Abuhamad AZ Kolm P Mari G . Ultrasonographic fetal iliac length measurement in the screening for Down syndrome. Am J Obstet Gynecol 1994; 171: 1063.

Bahado-Singh RO Wyse L Dorr MA Copel JA O'Connor T Hobbins JC . Fetuses with Down syndrome have disproportionately shortened frontal lobe dimensions on ultrasonographic examination. Am J Obstet Gynecol 1992; 167: 1009–14.

Chitty LS Hunt GH Moore J Lobbo MO . Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ 1991; 303: 1165–9.

Shirley IM Bottomley F Robinson VP . Routine radiographer screening for fetal abnormalities by ultrasound in an unselected low risk population. Br J Radiol 1992; 65: 564–9.

Roberts AB Hampton G Wilson N . Ultrasound detection of fetal structural abnormalities in Auckland 1988–9. N Z Med J 1993; 106: 441–3.

Goncalves LF Jernty P Piper JM . The accuracy of prenatal ultrasonography in detecting congenital anomalies. Am J Obstet Gynecol 1994; 171: 1606–12.

Stoll C Alembik Y Dott B Roth M . Epidemiology of Down syndrome in 118, 265 consecutive births. Am J Med Genet Suppl 1990; 7: 78–83.

Khoury MJ Erickson JD . Improved ascertainment of cardiovascular malformations in infants with Down's syndrome, Atlanta 1968 through 1989. Am J Epidemiol 1992; 136: 1457–64.

Burn J Goodship J . Congenital heart disease. In: Rimoin DL Connon JM Pyeritz RE , eds. Emery and Rimoin's principles and practice of medical genetics. 3rd ed. Edinburgh: Churchill Livingstone 1996: 767–803.

Connor JM Ferguson-Smith MA . Essential medical genetics. 4th ed. Oxford: Blackwell 1993.

Morris JK Mutton DE Ide R Alberman E Bobrow M . Monitoring trends in prenatal diagnosis of Down's syndrome in England and Wales, 1989–92. J Med Screen 1994; 1: 233–7.

Brambati B Simoni G Bonacchi I Piceni L . Fetal chromosomal aneuploidies and maternal serum AFP levels in the first trimester. Lancet 1986; ii: 165–6. (Data in Milunsky et al 1988.⁵).

Scioscia A Green J Robinson J Blakemore K Mahoney M Baumgarten A . Maternal serum AFP in normal first trimester pregancies and pregnancies with fetal anomalies [abstract]. Am J Hum Genet 1987; 41 (suppl): A285.

Cuckle HS Wald NJ Barkai G . First trimester biochemical screening for Down's syndrome. Lancet 1988; ii: 851–2. (For AFP the data exclude six cases in Fuhrmann et al 199322 and eight cases in Brambati et al 19861 and Milunsky et al 1988.5).

Barkai G Shaki R Pariente C Goldman B . First trimester AFP levels in normal and chromosomally abnormal pregnancies. Lancet 1987; ii: 389. (Data in Cuckle et al 1988.³).

Milunsky A Wands J Brambati B Bonacchi I Currie K . First trimester maternal serum AFP screening for chromosome defects. Am J Obstet Gynecol 1988; 159: 1209–13.

Mantingh A Marrink J de Wolf B Breed ASPM Beekhuis JR Visser GHA . Low maternal serum AFP at 10 weeks gestation and fetal Down's syndrome. Br J Obstet Gynaecol 1989; 96: 499–500.

Brock DJH Barron L Holloway S Liston WA Hillier SG Seppala M . First trimester maternal serum biochemical indicators in Down's syndrome. Prenat Diagn 1990; 10: 245–51.

Nebiolo L Ozturk M Brambati B Miller S Wands J Milunsky A . First trimester maternal serum AFP and hCG screening for chromosome defects. Prenat Diagn 1990; 10: 575–81. (Data in Milunsky et al.⁵).

Ozturk M Milunsky A Brambati B Sachs ES Miller SL Wands JR . Abnormal maternal levels of hCG subunits in trisomy 18. Am J Med Genet 1990; 36: 480–3.

Crandall BF Golbus MS Goldberg JD Matsumoto M . First trimester maternal serum uE, and AFP in fetal Down's syndrome. Prenat Diagn 1991; 11: 377–80.

Johnson A Cowchock FS Darby M Wapner R Jackson LG . First trimester maternal serum AFP and hCG in aneuploid pregnancies. Prenat Diagn 1991; 11: 443–50.

Kratzer PG Golbus MS Sorg ND Jones OW . hCG, free alpha-hCG and progesterone. Prenat Diagn 1991, 11: 751–65.

Van Lith JMM . First trimester screening for fetal chromosomal abnormalities. Preliminary results. Prenat Diagn 1991; 11: 621–4. (Data on AFP in Van Lith et al 1994³⁸; data on CA 125 updated by Van Lith et al 1993²⁹).

Van Lith JMM Mantingh A Beekhuis JR de Bruijn HWA . First trimester CA125 in Down's syndrome. Br J Obstet Gynaecol 1991; 98: 493–4. (Data in Van Lith et al 1993²⁹).

Hogdall CK Hogdall EVS Arends J Noorgard-Pedersen B Smidt-Jensen S Larsen SO . CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters. Prenat Diagn 1992; 12: 223–7.

Van Lith JMM for the Dutch Working Party on Prenatal Diagnosis. First trimester maternal serum hCG as a marker for fetal chromosomal disorders. Prenat Diagn 1992; 12: 495–504.

Wald NJ Stone R Cuckle HS . First trimester concentrations of PAPP-A and placental protein 14 in Down's syndrome. BMJ 1992; 30S: 28.

Aitken DA McKinnon D Crossley JA . Changes in the maternal serum concentrations of PAPP-A and SP1 in Down's syndrome pregnancies between the first and second trimesters [abstract]. Fourth conference: Endocrinology and metabolism in human reproduction. London: Royal College of Obstetrics and Gynaecology, May 1993.

Aitken DA McCaw G Crossley JA . First trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. Prenat Diagn 1993; 13: 681–9. (Data on AFP, uE₃₉ and free β-hCG are in Spencer et al 1994³⁴).

Brambati B Macintosh MCM Teisner B . Low maternal serum levels of PAPP-A in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993; 100: 324–6.

Crandall BF Hanson FW Keener S Matsumoto M Miller W . Maternal serum screening for AFP, uE, and hCG between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities. Am J Obstet Gynecol 1993; 168: 1864–9.

Fuhrmann W Altland K Jovanovic V . First trimester AFP screening for Down's syndrome. Prenat Diagn 1993; 13: 215–18.

Hurley PA Ward RHT Teisner B Lies RK Lucas M Grudzinskas JG . Serum PAPP-A measurements in first trimester screening for Down's syndrome. Prenat Diagn 1993; 13: 903–8.

Iles RK Sharma K Wathen NC . hCG, free subunit and PAPP-A composition of maternal serum in normal and Down's syndrome pregnancies [abstract]. Fourth conference: Endocrinology and metabolism in human reproduction. London: Royal College of Obstetrics and Gynaecology, May 1993.

Macintosh MCM Brambati B Chard T Grudzinskas JG . First trimester maternal serum SP1 in pregnancies associated with chromosomal anomalies. Prenat Diagn 1993; 13: 563–8.

Macri JN Spencer K Aitken D . First trimester free beta-hCG screening for Down's syndrome. Prenat Diagn 1993; 13: 557–62.

Muller F Cuckle HS Teisner B Grudzinskas JG . Serum PAPP-A levels are depressed in women with fetal Down's syndrome in early pregnancy. Prenat Diagn 1993; 13: 633–6.

Pescia G Marguerat PH Weihs D . First trimester free beta-hCG and SPl as markers for fetal chromosome disorders: a prospective study of 250 women undergoing CVS [abstract]. Fourth conference: Endocrinology and metabolism in human reproduction. London: Royal College of Obstetrics and Gynaecology, May 1993.

Van Lith JMM Mantingh A Bruijn HWA . Maternal serum CA 125 levels in pregnancies with chromosomally normal and abnormal fetuses. Prenat Diagn 1993; 13: 1123–31.

Bersinger NA Brizot ML Johnson A . First trimester maternal serum pregnancy associated plasma protein A and pregnancy specific β 1-glycoprotein in fetal trisomies. Br J Obstet Gynaecol 1994; 101: 970–4. (Data on PAPP-A in Brizot et al 1994.31 and on SPl in Brizot et al 1995.42).

Brizot ML Snijders RJM Bersinger NA Kuhn P Nicolaides KH . Maternal serum pregnancy associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994; 84: 918–22.

Brambati B Tului L Bonacchi I . Serum PAPP-A and free beta-hCG are first trimester screening markers for Down's syndrome. Prenat Diagn 1994; 14: 1043–7.

Macintosh MCM Iles R Teisner B . Maternal serum hCG and PAPP-A, markers for fetal Down syndrome at 8–14 weeks. Prenat Diagn 1994; 14: 203–8. (Some data contained in Hurley et al 1993²³ and Macri et al 1993²⁶).

Spencer K Aitken DA Crossley JA . First trimester biochemical screening for trisomy 21: the role of free beta-hCG, AFP and PAPP-A. Ann Clin Biochem 1994; 31: 447–54.

Van Lith JMM . First trimester maternal serum PAPP-A levels in pregnancies with chromosomally normal and abnormal fetuses. Holland: Groningen University 1994. (PhD thesis, chapter 5.).

Van Lith JMM for the Dutch Working Party on Prenatal Diagnosis. First trimester maternal serum AFP as a marker for fetal chromosomal disorders. Prenat Diagn 1994; 14: 963–71.

Van Lith JMM Mantingh A Pratt JJ . First trimester maternal serum immunoreactive inhibin in chromosomally normal and abnormal pregnancies. Obstet Gynecol 1994; 83: 661–4.

Wallace EM Harkness LM Burns S Liston WA . Evaluation of maternal serum immunoreactive inhibin as a first trimester marker of Down's syndrome. Clin Endocrinol 1994; 41: 483–6.

Biagiotti R Cariati E Brizzi L D'Agata A . Maternal serum screening for Down's syndrome in the first trimester of pregnancy. Br J Obstet Gynaecol 1995; 102: 660–2.

Brizot ML Kuhn P Bersinger NA Snijders RJM Nicolaides KH . First trimester maternal serum alpha-fetoprotein in fetal trisomies. Br J Obstet Gynaecol 1995; 102: 31–4.

Brizot ML Snijders RJM Butler J Bersinger NA Nicolaides KH . Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 1995; 102: 127–32.

Brizot ML Bersinger NA Xydias G Snijders RJM Nicolaides KH . Maternal serum schwangerschafts protein 1 (SP-1) and fetal chromosomal abnormalities at 10–13 weeks' gestation. Early Hum Dev 1995; 43: 31–6.

Forest JC Masse J Rousseau F . Screening for Down's syndrome during the first and second trimesters: impact of risk estimation parameters. Clin Biochem 1995; 28: 443–9.

Krantz D Larsen J Buchanan P Macri J . First trimester Down syndrome screening: free βhCG and PAPP-A [abstract]. Am J Obstet Gynecol 1995; 260: A19. (Data in Krantz et al 1996.47).

Wallace EM Grant VE Swanston LA Groome NP . Evaluation of maternal serum dimeric inhibin A as a first trimester marker of Down's syndrome. Prenat Diagn 1995; 1S: 359–62.

Aitken DA Wallace EM Crossley JA . Dimeric inhibin-A as a marker for Down's syndrome in early pregnancy. N Engl J Med. 1996; 334: 1231–6. (Data on AFP, hCG, and β-hCG in Spencer et al 1994³⁴ and Aitken et al 1993¹⁸).